This suggests that GPR4 may have both anti and pro-tumour effects dependant on cell type, which may limit the clinical application of compounds that increase or limit GPR4 activation, until further research clarifies the possible mechanisms involved. This evidence concerns the gene GPR4 and neoplasm.